Share this video  

ESMO 2023 | INTERLACE: induction chemotherapy + CRT as new SOC in locally advanced cervical cancer

In locally advanced cervical cancer (LACC), chemoradiation (CRT) is a standard treatment, but metastatic relapse remains a challenge. Mary McCormack, BSc, MSc, PhD, MBBS, University College London Hospitals NHS Foundation Trust, London, UK, discusses results from the INTERLACE trial which investigated the efficacy of short-course weekly induction chemotherapy followed by standard CRT. Eligible women with specified cancer stages were randomized to receive either CRT alone or induction chemotherapy followed by CRT. Results from 500 patients across 32 centers in 5 countries show that induction chemotherapy/CRT significantly improves progression-free survival (PFS) and overall survival (OS) compared to CRT alone. Adverse events were slightly higher in the induction chemotherapy/CRT group. The study suggests that induction chemotherapy followed by CRT should be considered a new standard of care for LACC. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.